CD47 and neoplasm: NSC87877 (paclitaxel) demonstrated significant efficacy against high-risk DLBCL, which is consistant with its role in microtubule stabilization40, epigenetic modulation via HDACi synergy41, and remodeling tumor microenvironment to in CD47-targeted therapy42.